Danaher companies Integrated DNA Technologies (IDT), a global leader in genomics, and Aldevron, a premier manufacturing partner for DNA, RNA, and protein, today announced the launch of research grade S.p. Cas9 mRNA in wild type and SpyFi™ high-fidelity formats. The new offering gives researchers and therapeutic developers access to high-quality Cas9 mRNA for CRISPR-based genome editing workflows, with performance, format flexibility, and manufacturing continuity designed to help advanced gene editing programs move from research toward development with greater confidence.
Gene editing researchers are under pressure to move faster without compromising performance, reproducibility or flexibility, By connecting IDT’s CRISPR protein engineering expertise, with Aldevron’s mRNA manufacturing capabilities, scientists will now have access to an optimized Cas9 mRNA offering designed to support efficient editing, reduced off-target risk, and greater continuity as their programs advance. It’s a strong example of how connected expertise across Danaher companies can help researchers reduce complexity and move promising science forward with greater speed and confidence.”
Christopher Vakulskas, Senior Director, Applied Science and Molecular Design, Integrated DNA Technologies
As gene editing advances toward clinically relevant ex vivo and in vivo applications, customers need CRISPR mRNA reagents that deliver reproducible editing performance, reduce technical risk, support emerging delivery approaches, and fit into programs that may ultimately need to scale. IDT and Aldevron’s co-developed Cas9 mRNA directly addresses these challenges through optimized constructs manufactured in consistent research grade formats, with a path to scaled CGMP-manufactured versions as programs progress.
Addressing a Critical Need in Translational Gene Editing
The new offering is designed to support high on-target editing efficiency across multiple cell types, including T cells, iPSCs and immortalized cells, while the SpyFi high-fidelity version helps reduce off-target editing risk. The mRNA formats are compatible with delivery via electroporation, cationic lipids, and lipid nanoparticles (LNP), giving customers flexibility to select the approach that best fits their application.
The Cas9 mRNA is enzymatically capped, providing customers with a high-performing alternative to certain proprietary capping technologies. By reducing licensing burden and simplifying access, the offering helps researchers focus on advancing their science rather than managing licensing complexity.
Creating a More Connected Path From Discovery to Development
By introducing Cas9 mRNA as part of a broader IDT and Aldevron gene editing workflow, the companies are expanding the options available to customers who need reliable, high-performance research tools, scientific support and continuity across CRISPR design, analysis, RNA manufacturing, and future scale-up. This launch is the first in a suite of co-developed offerings, with base and prime editors slated later this year.
With a rich history of working together to provide customers with critical tools and manufacturing support for genomic medicine workflows, IDT and Aldevron are building on that foundation to equip customers with a new mRNA modality option for Cas9-based gene editing. The solution combines IDT’s guide RNA design and analysis expertise and Aldevron’s mRNA manufacturing capabilities - the result is a streamlined experience for customers advancing Cas9-based gene editing programs from early research through CGMP manufacturing.